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Abstract
Intra-tumour heterogeneity is a common molecular phenomenon in metastatic clear cell renal carcinoma (mRCC),
representing the genetic complexity of a tumour with multiple metastatic sites. The present commentary discusses
the observed phenomena of phenotypic intra-tumour heterogeneity in mRCC patients treated with the tyrosine
kinase inhibitors sunitinib or pazopanib. Here, drug response can be different on the level of each evaluated
metastasis in the individual patient. This questions the currently used radiologic staging systems of RECIST criteria
and demands for a modification of radiologic response assessment with the consequence of a patient-tailored
therapy in the clinical setting.
Please see related article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0729-9.
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Background
Renal cell carcinoma (RCC) is a multifaceted tumour.
The same histopathological subtype, stage and grade in
clear cell RCC demonstrates a different tumour behav-
iour among patients, called inter-tumour heterogeneity
(ITH) [1]. ITH is a common phenomenon defined by
different subpopulations of cells with distinct genomic
alterations and phenotypes between the primary tumour
and the respective metastases within one patient [2].
Natural selection is the backbone of ITH, leading to an
accumulation of genetic alterations in genetically un-
stable cells through which a selection pressure drives the
growth and survival of distinct subpopulations, mirror-
ing a biological fitness advantage. These mechanisms of
clonal evaluation and genomic instability of the cancer
cell contribute to molecular heterogeneity within the
tumours, leading to subclones that are likely to have a
growth or survival advantage [3]. The evidence for this
genetic diversity both between different tumours and
within a single tumour has been derived from new tech-
nologies such as next-generation sequencing. Gerlinger
et al. [2] revealed extensive ITH by exome sequencing of
multiple tumour samples from primary and metastatic
lesions in patients with clear cell RCC. Indeed, there is
evidence of multiple, genetically distinct subclones
within primary tumours or in primary tumours and their
metastases [2]. Further, subclonal driver mutations may
contribute to the acquisition of drug resistance [4]. This
known fact of molecular ITH is likely to influence can-
cer therapeutics and to result in heterogeneous or mixed
response patterns as observed by imaging.
Considerable progress has been made in the treatment
of metastatic RCC (mRCC), with an improvement of
overall survival following the implementation of anti-
angiogenic tyrosine kinase inhibitors (TKIs) since 2006
[5]. Complete response (CR) is a rare event with TKIs;
however, partial response (PR) is achieved in 10–39% of
patients [6, 7]. In the case of a PR, an additional benefit
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from surgical resection of residual metastases is observed,
achieving prolonged disease control [7, 8]. Nevertheless,
the majority of advanced diseases reveal that the first ob-
served clinical benefit is often of limited duration, with
most patients exhibiting disease progression [9]. There-
fore, the identification of distinct response and progres-
sion patterns in the treatment of mRCC is critical. The
Response Evaluation Criteria In Solid Tumours (RECIST
1.1 criteria) is the currently accepted method to provide a
radiographic definition for CR, PR, stable disease (SD) and
progression, and thereby defines progression-free survival
time in mRCC [10]. The RECIST method is based on
morphologic changes, specifically the change in the sum
of the longest dimensions of the target lesions.
Phenotypic heterogeneity
In a recent article, Crusz et al. [11] hypothesized that
the molecular ITH is mirrored by clinical heterogeneity,
observed by a subset of metastases responding and pro-
gressing within the same patient. In their study, a radio-
logical analysis of patients with two or more assessable
metastatic lesions that progressed under therapy with
anti-angiogenic TKIs (sunitinib or pazopanib), based on
the population of three similar phase II trials, was per-
formed. For the analysis of the study population (n = 27
patients with multiple metastases) each metastasis was
evaluated based on the principles of RECIST 1.1 to
define responding, stable or progressing lesions. A het-
erogeneous drug response was defined as the deviation
of response patterns within one patient, while a ho-
mogenous response was defined as all lesions falling
within the same response category. Heterogeneous re-
sponse was detectable in 56% (15/27) of patients and
homogenous response in 44%. There was no difference
in heterogeneous response in patients who had a sub-
optimal dosing through dose reductions or those that
underwent nephrectomy. Reason for progressions was
mainly the appearance of new lesions (67%), while the
progression of existing lesions was a rare event (11%);
22% of patients exhibited both.
In clinical practice, the decision to switch or to con-
tinue a given systemic therapy is a common challenge,
especially in the presence of heterogeneous progression
and response patterns. Thus, the identification of cancer
types with a respective heterogeneous response pattern
is likely to influence clinical decision-making and, there-
fore, clinical outcome. As shown, a clinical ITH was
observed for mRCC upon sunitinib or pazopanib treat-
ment [11]. The occurrence of new lesions, which was
the main cause for the definition of progression, ques-
tions the applicability of the currently used RECIST 1.1
criteria, particularly considering that progression-free
survival, which is one of the main parameters in the as-
sessment of clinical trials, is presently determined by
RECIST 1.1 analysis. Currently, the applied therapy is
discontinued and alternative treatments are initiated
when the patient meets progression-defined parameters
by RECIST criteria such as the occurrence of new (small)
lesions even if several large lesions remain controlled.
Studies with monoclonal antibodies or cytokines have
shown that an increase in total tumour burden, for
example, by oedema or inflammation, both of which are
defined as progressive disease by WHO and RECIST
criteria, is later followed by sustained tumour regression
seen as CR, PR and SD. The development of novel criteria,
designated as immune-related response criteria, was based
on data from ipilimumab clinical trials in melanoma [12].
These criteria incorporate measurable new lesions into
total tumour burden and compare this to baseline mea-
surements [12]. Thus, patients are considered to have PR
or SD even if new lesions present, provided that the
tumour burden of all lesions meets the determined thresh-
olds. According to this definition, if new, small metastatic
lesions occur (defined as PD by RECIST) while the bulk of
the disease remains controlled, therapy should not be
changed, but rather should be continued. The immune-
related response criteria acknowledge heterogeneous re-
sponse patterns, although their underlying principle is an
immune-related event defined as pseudoprogression [10]
and not, as shown by Crusz et al. [11], of ITH. Likewise,
novel imaging approaches like functional imaging, but also
the adjustment of current response criteria, which do not
automatically consider the appearance of new lesions as a
PD, could further assist to detect metastases that differ in
their individual biological characteristics. One clinical
consequence is a tailored therapy with the resection of the
progressing lesion(s), a molecular analysis form biopsy tis-
sue and, if possible, the expansion of systemic therapy to
optimise patient care as well as clinical outcome.
Conclusions
The aim of targeted therapy is to inhibit the critical pro-
liferation or survival pathways on which the tumour
depends. This VEGF-based strategy has significantly im-
proved patient outcomes in mRCC within the last years.
The underlying tumour biology demonstrates that the
majority of somatic gene mutations are not ubiquitously
present within a tumour, but is rather characterised by
the existence of subclones derived from a common
clonal progenitor, with variations between different re-
gions of the same tumour and metastases [2]. As a clin-
ical result, metastatic lesions of the same patients might
show heterogeneous progression patterns in radiologic
imaging due to different drug sensitivity as reported by
Crusz et al. [11]. Currently, the RECIST 1.1 classification
is widely used to determine response assessment, but does
not acknowledge phenotypic ITH. The clinical conse-
quence in RECIST 1.1-defined progression is the switch to
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another line of therapy, rather than the continuation of
therapy with or without the resection of the resistant le-
sion. According to molecular findings, systemic therapy
could be, if possible, expanded to another active agent.
Currently, this is not satisfactorily reflected in radiologic
response assessment with the need for modification of
radiologic classifications, especially when used in clinical
trials of mRCC patients.
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